HLA-Typed Cytotoxic T-Cell Selection Algorithm
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting viral-specific cytotoxic T-cell lines for therapy do not effectively match individual patient needs, leading to potential deleterious immune responses and reduced therapeutic efficacy.
Innovation Solution
A system and method that utilize HLA typing and mathematical formulas to identify the most suitable viral-specific cytotoxic T-cell line for a patient by matching HLA alleles and measuring reactive frequencies of CD4+ and CD8+ cells, determining a cell line identification number based on weighted values for HLA matching and cell reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral-specific CTL lines are selected without individualized matching methods, then the selection process is simple and quick, but therapeutic efficacy is reduced and deleterious immune responses occur
Solution Approach 1:
The patent performs HLA typing and reactive frequency measurements for multiple CTL lines in advance, before patient treatment is needed. This preliminary characterization allows the selection system to quickly match patients with appropriate CTL lines based on pre-calculated compatibility data, rather than performing extensive testing at the time of treatment decisions
Solution Approach 2:
The patent introduces a computerized selection system that acts as an intermediary between patient HLA data and CTL line characteristics. This system calculates HLA matching scores and reactive frequencies to objectively identify the most suitable CTL lines, eliminating the need for complex manual evaluation while improving selection accuracy
2Measurement precision
If HLA typing and reactive frequency measurements are performed for all CTL lines, then matching precision is improved, but time consumption and resource requirements increase
Solution Approach 1:
The patent performs HLA typing and reactive frequency measurements for all available CTL lines in advance, during the cell line development and banking phase. This preliminary characterization creates a comprehensive database that enables rapid patient-CTL matching without requiring extensive testing at the time of treatment decisions
Solution Approach 2:
The patent creates a digital representation (copy) of each CTL line's HLA profile and reactive frequency characteristics in a database. This digital copy allows the selection system to evaluate multiple CTL lines against patient data instantly, without requiring physical manipulation or re-testing of the actual cell lines during the selection process
Data Source
AI summary
Embodiments of the disclosure concern systems, methods, and compositions related to identification of a suitable cell therapy for an individual in need thereof. A cell line is selected from a plurality of cell lines for suitability for an individual based on an algorithm and cell identification number that includes values for HLA matching and the frequency of reactive CD4 and CD8 cytotoxic T lymphocytes as measured by interferon-γ and IL-2. Particular parameters for HLA matching and reactive frequencies are utilized to calculate points towards the cell identification number, and the cell line with the highest cell identification number may be utilized.